E2F transcription factors and digestive system malignancies: How much do we know?

World Journal of Gastroenterology

Volumn , Issue 29, 2014, Pages 10212-10216

  Evangelou, Konstantinos ^a   Havaki, Sophia ^a   Kotsinas, Athanassios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apoptosis; Cancer; Digestive system; E2F; Gastrointestinal tract; Hepatocellular carcinoma; p53; p73; Pancreatic ductal adenocarcinoma; Proliferation

Indexed keywords

ARF PROTEIN; ATM PROTEIN; CHECKPOINT KINASE 2; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; NIBRIN; PROTEIN BCL XL; PROTEIN P16; PROTEIN P53; PROTEIN P68; PROTEIN P73; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F5; TRANSCRIPTION FACTOR E2F6; TRANSCRIPTION FACTOR E2F7;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; DIGESTIVE SYSTEM CANCER; GENE MUTATION; GENE OVEREXPRESSION; GENE REGULATORY NETWORK; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PANCREAS ADENOCARCINOMA; PEG 10 GENE; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; DIGESTIVE SYSTEM TUMOR; METABOLISM; CARCINOMA CELL; CELL FATE; DISEASE FREE SURVIVAL; PANCREAS CANCER; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CARCINOGENESIS; DIGESTIVE SYSTEM NEOPLASMS; E2F TRANSCRIPTION FACTORS; HUMANS;

EID: 84905841925     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i29.10212     Document Type: Article

References (35)

1. Xanthoulis A, Tiniakos DG. E2F transcription factors and digestive system malignancies: how much do we know? World J Gastroenterol 2013; 19: 3189-3198 [PMID: 23745020 DOI: 10.3748/wjg.v19.i21.3189]
2. Kherrouche Z, De Launoit Y, Monté D. Human E2F6 is alternatively spliced to generate multiple protein isoforms. Biochem Biophys Res Commun 2004; 317: 749-760 [PMID: 15081404 DOI: 10.1016/j.bbrc.2004.03.099]
3. Müller H, Moroni MC, Vigo E, Petersen BO, Bartek J, Helin K. Induction of S-phase entry by E2F transcription factors depends on their nuclear localization. Mol Cell Biol 1997; 17: 5508-5520 [PMID: 9271426]
4. Verona R, Moberg K, Estes S, Starz M, Vernon JP, Lees JA. E2F activity is regulated by cell cycle-dependent changes in subcellular localization. Mol Cell Biol 1997; 17: 7268-7282 [PMID: 9372959]
5. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, Miron A, Nevins JR. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol 2000; 20: 3626-3632 [PMID: 10779352 DOI: 10.1128/MCB.20.10.3626-3632.2000]
6. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol 2000; 20: 3633-3639 [PMID: 10779353 DOI: 10.1128/MCB.20.10.3633-3639.2000]
7. He Y, Cress WD. E2F-3B is a physiological target of cyclin A. J Biol Chem 2002; 277: 23493-23499 [PMID: 11980909 DOI: 10.1074/jbc.M202629200]
8. Tsantoulis PK, Gorgoulis VG. Involvement of E2F transcription factor family in cancer. Eur J Cancer 2005; 41: 2403-2414 [PMID: 16213134 DOI: 10.1016/j.ejca.2005.08.005]
9. Liontos M, Niforou K, Velimezi G, Vougas K, Evangelou K, Apostolopoulou K, Vrtel R, Damalas A, Kontovazenitis P, Kotsinas A, Zoumpourlis V, Tsangaris GT, Kittas C, Ginsberg D, Halazonetis TD, Bartek J, Gorgoulis VG. Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. Am J Pathol 2009; 175: 376-391 [PMID: 19541929 DOI: 10.2353/ajpath.2009.081160]
10. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9: 785-797 [PMID: 19851314 DOI: 10.1038/nrc2696]
11. Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene 2000; 19: 5054-5062 [PMID: 11042693 DOI: 10.1038/sj.onc.1203885]
12. Engelmann D, Pützer BM. The dark side of E2F1: in transit beyond apoptosis. Cancer Res 2012; 72: 571-575 [PMID: 22298593 DOI: 10.1158/0008-5472.CAN-11-2575]
13. Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, Bekele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 2007; 67: 4005-4009 [PMID: 17483310 DOI: 10.1158/0008-5472.CAN-06-2973]
14. Yamazaki K, Yajima T, Nagao T, Shinkawa H, Kondo F, Hanami K, Asoh A, Sugano I, Ishida Y. Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study. Pathol Res Pract 2003; 199: 23-28 [PMID: 12650514 DOI: 10.1078/0344-0338-00348]
15. Plath T, Peters M, Detjen K, Welzel M, von Marschall Z, Radke C, Wiedenmann B, Rosewicz S. Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J Natl Cancer Inst 2002; 94: 129-142 [PMID: 11792751 DOI: 10.1093/jnci/94.2.129]
16. Elliott MJ, Farmer MR, Atienza C, Stilwell A, Dong YB, Yang HL, Wong SL, McMasters KM. E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Tumour Biol 2002; 23: 76-86 [PMID: 12065845 DOI: 10.1159/000059708]
17. Rödicker F, Stiewe T, Zimmermann S, Pützer BM. Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res 2001; 61: 7052-7055 [PMID: 11585734]
18. DeGregori J, Johnson DG. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr Mol Med 2006; 6: 739-748 [PMID: 17100600]
19. Chen YL, Uen YH, Li CF, Horng KC, Chen LR, Wu WR, Tseng HY, Huang HY, Wu LC, Shiue YL. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma. Ann Surg Oncol 2013; 20: 4041-4054 [PMID: 22911364 DOI: 10.1245/s10434-012-2519-8]
20. Simile MM, De Miglio MR, Muroni MR, Frau M, Asara G, Serra S, Muntoni MD, Seddaiu MA, Daino L, Feo F, Pascale RM. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis 2004; 25: 333-341 [PMID: 14604889 DOI: 10.1093/carcin/bgh014]
21. Wang C, Xiao Y, Hu Z, Chen Y, Liu N, Hu G. PEG10 directly regulated by E2Fs might have a role in the development of hepatocellular carcinoma. FEBS Lett 2008; 582: 2793-2798 [PMID: 18625225 DOI: 10.1016/j.febslet.2008.07.009]
22. Pascale RM, Simile MM, De Miglio MR, Muroni MR, Calvisi DF, Asara G, Casabona D, Frau M, Seddaiu MA, Feo F. Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis. Hepatology 2002; 35: 1341-1350 [PMID: 12029619 DOI: 10.1053/jhep.2002.33682]
23. Palaiologou M, Koskinas J, Karanikolas M, Fatourou E, Tiniakos DG. E2F-1 is overexpressed and pro-apoptotic in human hepatocellular carcinoma. Virchows Arch 2012; 460: 439-446 [PMID: 22450712 DOI: 10.1007/s00428-012-1220-4]
24. Croxton R, Ma Y, Song L, Haura EB, Cress WD. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002; 21: 1359-1369 [PMID: 11857079 DOI: 10.1038/sj.onc.1205157]
25. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2004; 2: 203-214 [PMID: 15140942]
26. Jiang Y, Yim SH, Xu HD, Jung SH, Yang SY, Hu HJ, Jung CK, Chung YJ. A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma. World J Gastroenterol 2011; 17: 470-477 [PMID: 21274376 DOI: 10.3748/wjg.v17.i4.470]
27. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-3130 [PMID: 9242437]
28. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734 [PMID: 9135016]
29. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TR, Sansom OJ. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010; 107: 246-251 [PMID: 20018721 DOI: 10.1073/pnas.0908428107]
30. Huynh H, Do PT, Nguyen TH, Chow P, Tan PH, Quach TH, Van T, Soo KC, Tran E. Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. Int J Oncol 2004; 25: 1839-1847 [PMID: 15547725]
31. Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F, Hauss J, Wittekind C. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 2001; 20: 7104-7109 [PMID: 11704835 DOI: 10.1038/sj.onc.1204902]
32. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007; 26: 2166-2176 [PMID: 17401425 DOI: 10.1038/sj.onc.1210279]
33. Mihara M, Nimura Y, Ichimiya S, Sakiyama S, Kajikawa S, Adachi W, Amano J, Nakagawara A. Absence of mutation of the p73 gene localized at chromosome 1p36.3 in hepatocellular carcinoma. Br J Cancer 1999; 79: 164-167 [PMID: 10408709 DOI: 10.1038/sj.bjc.6690027]
34. Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS. E2F1 inhibits c-Myc-driven apoptosis via PIK-3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008; 135: 1322-1332 [PMID: 18722373 DOI: 10.1053/j.gastro.2008.07.012]
35. Watanabe J, Kushihata F, Honda K, Sugita A, Tateishi N, Mominoki K, Matsuda S, Kobayashi N. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 2004; 135: 604-612 [PMID: 15179366 DOI: 10.1016/j.surg.2003.11.015]